- Journal Facts
- Journal Scope and Content
- Posting Dates
- Instructions for Submission
- AAI Annual Meeting Abstracts
- AAI Disclaimer
The Journal of Immunology
1451 Rockville Pike, Suite 650
Rockville, MD 20852
- Publisher: The Journal of Immunology (The JI) is owned and published by The American Association of Immunologists, Inc.
- Editor-in-Chief: Pamela J. Fink, Ph.D. email@example.com
- Editorial Board: The Journal of Immunology Editorial Board. All Editors are practicing scientists.
- The Staff: The JI Staff Members
- Impact factor:
- Two-year: 4.985 (2015 Journal Citation Reports)
- Five-year: 5.287 (2015 Journal Citation Reports)
- Citations: The JI is cited more than any other immunology journal (2015 Journal Citation Reports)
- Number of research articles published/year: 1,129 (2015)
- Number of pages published/year: 11,900 (2015)
- Around 1.8 million page views per month
- Over 440,000 PDF downloads per month
- Publication schedule: Printed and posted online twice each month
- Issue dates: 1st and the 15th of each month
- Average time from submission to initial decision (full-length manuscripts): 30 days (2015)
- Average time from acceptance to print: 7.4 weeks (2015)
- Acceptance rate: 47% for full-length papers, 28% for Cutting Edge papers (2015)
- Online ISSN: 1550-6606 Print ISSN: 0022-1767
- Full-Length Articles
- Cutting Edge Articles
- Brief Reviews
- Pillars of Immunology
- Letters to the Editor
- In This Issue
- Translating Immunology
- Immunology Notes and Resources
Manuscripts are published in the following sections:
- Allergy and Other Hypersensitivities
- Antigen Recognition and Responses
- Clinical and Human Immunology
- Immune Regulation
- Immune System Development
- Immunotherapy and Vaccines
- Infectious Disease and Host Response
- Innate Immunity and Inflammation
- Molecular and Structural Immunology
- Mucosal Immunology
- Systems Immunology
Manuscripts submitted to the “Systems Immunology” Table of Contents section should center on analyses of novel large data sets, generated by the authors, which will serve as useful resources for future work in the field. The authors’ informatics analyses should allow them to draw concrete conclusions, supported by the data, about the biology of the system(s) under study. Alternatively, manuscripts may describe a novel method of data analysis, which could be applied to publicly available data sets. The latter type of manuscript must convincingly demonstrate the utility of the new analysis method to reveal novel biological insights about the system(s) under study. However, it is not necessary for either type of manuscript to include definitive mechanistic analysis or experiments beyond those necessary for the acquisition of reproducible and meaningful data sets.
- Tumor Immunology
- Novel Immunological Methods (see Editorial)
Manuscripts submitted to the Novel Immunological Methods section should provide a new approach to important immunological problems. The manuscript should validate the technique, reagent, or genetically manipulated line of mice (and provide data on that) and indicate their utility for solving an immunologically interesting problem, but it is not necessary for the manuscript to solve that problem. The manuscript is evaluated on whether the technique, reagent, or line of mice is better than what is currently available and could therefore advance the field, as well as the usefulness of the technique, reagent, or line of mice to the field.
As a point of reference, descriptions of the following would only be appropriate if they provide innovative insight into unresolved immunological problems, reveal novel structural features that are unique in an immunologically relevant manner, or represent major breakthroughs in the field:
- New reagents
- T cell or B cell epitopes
- Peptide binding motifs for previously uncharacterized MHC products
- Structures of MHC allelic products or MHC-peptide complexes not previously crystallized or homologs from previously uncharacterized species
- Three-dimensional structures of allergens or other antigens, antibody-defined epitopes, or antigen-antibody complexes
- Comparative analysis of proteins of immunological interest (intra- or inter-species comparisons)
- Research techniques
- Clinical case reports
Those wishing to report the identification of epitopes may do so at the Immune Epitope Database and Analysis Resource.
Cutting Edge Articles: Cutting Edge is the rapid publication section of The JI, presenting short reports describing significant advances in an area of immunology. Manuscripts submitted for consideration in this section should present scientifically sound and novel research in a clear and concise fashion, and contain conclusions of unusual interest to immunologists that are justified from the data presented. Chief criteria for acceptance are scientific novelty and quality, originality, clarity, and conciseness. In addition to research articles, the Cutting Edge section publishes invited brief commentaries on controversial subjects of broad interest to immunologists.
Brief Reviews: The JI publishes a small number of invited reviews on a regular basis. These reviews are four to six journal pages in length, including illustrations and references. They cover a focused area on the advancing edge of immunology and provide a balanced view of current research that can be understood by researchers outside of that specialty. Authors interested in submitting an article to Brief Reviews should submit a proposal, including an outline of the proposed review, by e-mail to the Editor-in-Chief. See the collected Brief Reviews page.
Pillars Of Immunology: In the first issue of each month, The JI reprints papers that have come to be regarded as classics in the field. An invited commentary will accompany each reprinted article. Suggestions for significant articles may be made by e-mail to the Editor-in-Chief. See the collected Pillars Of Immunology page.
Letters To The Editor: The Editor-in-Chief invites brief letters (250 words or less) of general interest, commenting on work published in The JI within the previous three months. A limited number of letters will be selected for publication. The authors of the original work will be invited to respond, and both the original letter and the authors' response will be published together. If you are interested in commenting on a published paper, e-mail the Editor-in-Chief.
Translating Immunology Articles: These invited articles highlight immunological discoveries that have led to a treatment, drug, or diagnostic device. See the collected Translating Immunology page.
Immunology Notes And Resources is a feature where items of general interest to the immunology community may be published, such as articles on nomenclature or other significant items that may impact scientific research. These articles are published at the discretion of the Editor-in-Chief, who may seek advice from other editors or experts in the field. Submissions can be made by e-mail to the Editor-in-Chief.
THIS WEBSITE IS PROVIDED ON AN "AS IS" AND "AS AVAILABLE" BASIS, WITHOUT WARRANTIES OR REPRESENTATIONS OF ANY KIND (EXPRESS, IMPLIED OR STATUTORY, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE), ALL OF WHICH THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, INC., DISCLAIMS TO THE FULLEST EXTENT PERMITTED BY LAW.
In no event shall The American Association of Immunologists, Inc., be liable for any special, incidental, indirect or consequential damages of any kind, or any damages whatsoever resulting from loss of use, data or profits, whether or not advised of the possibility of damage, and on any theory of liability, arising out of or in connection with the use or performance of this information.
The ideas and opinions expressed in The Journal of Immunology do not necessarily reflect those of The American Association of Immunologists, Inc., or the Editors or staff of The Journal of Immunology.
The American Association of Immunologists, Inc., neither endorses nor takes responsibility for any products, goods or services offered by outside vendors through its services or advertisements.
Your use of the site is at your sole risk and by use of this site you agree that the exclusions and limitations of liability in this Disclaimer are reasonable.